EGCG Supplement

## What it is Epigallocatechin gallate (EGCG) is the most abundant and most studied catechin in Camellia sinensis (green tea), accounting for roughly 50 to 70% of the total catechin content depending on cultivar and processing. A standard cup of brewed green tea delivers around 50 to 100 mg of EGCG, while concentrated extracts standardized to 45 to 90% catechins deliver 200 to 600 mg per capsule. The molecule was first isolated in the 1930s, and the modern interest in EGCG as a metabolic and chemopreventive supplement traces to a series of Japanese epidemiological studies in the 1980s and 1990s linking high green tea consumption to lower cardiovascular and cancer mortality. Legally EGCG and green tea extracts are dietary supplements in the United States, Canada, Australia, and most of the EU. The European Food Safety Authority issued a 2018 opinion concluding that EGCG doses at or above 800 mg/day from supplements may be associated with hepatotoxicity, and several EU member states (including Spain and Sweden) now require warning labels on green tea extracts above 800 mg/day. The hepatotoxicity signal is real but rare, and mostly associated with high-dose extracts taken on an empty stomach. WADA does not list EGCG. The catechin is one of three sources of bioactivity in green tea, alongside L-theanine (the calming amino acid) and caffeine. Whole green tea extract, decaffeinated green tea extract, and isolated EGCG produce different pharmacological profiles, and the literature does not always cleanly distinguish between them. Most fat-loss trials use whole extracts in which caffeine and EGCG act additively on thermogenesis; isolated EGCG without caffeine produces smaller effects on energy expenditure. ## Mechanism of action EGCG has a wide and not-fully-characterized pharmacology. The mechanisms with the strongest evidence are catechol-O-methyltransferase (COMT) inhibition, which prolongs the half-life of norepinephrine and prolongs the thermogenic response to caffeine and exercise; AMPK activation, which produces metabolic effects similar to berberine and metformin at downstream points; and direct antioxidant activity through the gallate ester group, which scavenges reactive oxygen species and chelates transition metals. Additional mechanisms include modulation of the gut microbiome (EGCG is largely metabolized by intestinal bacteria, with substantial inter-individual variation in metabolite profiles); inhibition of dietary fat absorption through pancreatic lipase inhibition; and modulation of inflammatory signaling through NF-kB suppression. The complexity of the mechanism profile is part of why EGCG produces small effects across many systems rather than large effects in any single one. Bioavailability is the practical bottleneck. Oral bioavailability of free EGCG in healthy adults is typically 0.1 to 1.0%, with substantial variation by fed/fasted state, gut microbiome composition, and genetic differences in methyltransferase activity. Taking EGCG with food reduces absorption further. Plasma half-life after oral dosing is 2 to 4 hours. ## Evidence base by outcome ### Body weight and fat loss The Hursel 2009 meta-analysis pooled 11 RCTs of green tea extract for weight loss and reported a 1.31 kg average reduction over 12 weeks versus placebo, with the effect concentrated in studies that included caffeine alongside EGCG. The 2012 Cochrane review (18 trials) reported similar small effects with high heterogeneity. The dose-response is shallow: 300 mg/day and 600 mg/day produce similar effects, and going higher mostly increases side-effect burden. Effect sizes are smaller in caffeine-habituated populations (where the thermogenic response is blunted) and larger in caffeine-naive populations. ### Cardiovascular risk markers Green tea consumption is associated in epidemiological studies with 5 to 25% lower cardiovascular mortality, with the largest signal in the Japanese Ohsaki cohort (40,000 adults followed 11 years). Trials of green tea extract on intermediate markers show small reductions in LDL cholesterol (3 to 6 mg/dL), small reductions in systolic blood pressure (2 to 3 mmHg), and modest improvements in flow-mediated vasodilation. The translation from intermediate markers to hard cardiovascular endpoints in randomized trials remains thin. ### Glycemic control The Liu 2013 meta-analysis (17 trials, 1133 participants) reported small reductions in fasting glucose (0.09 mmol/L) and HbA1c (0.3%) in T2DM and prediabetic adults at 300 to 600 mg/day for 8 to 16 weeks. Effect sizes are smaller than berberine or metformin and the evidence is concentrated in Asian populations. C to B-tier; reasonable as part of a metabolic stack but underwhelming as monotherapy. ### Hepatotoxicity The EFSA 2018 opinion documented at least 64 cases of suspected EGCG-related hepatotoxicity in Europe, with most occurring at high-dose extracts above 800 mg/day, particularly when taken on an empty stomach. The mechanism is likely a combination of mitochondrial toxicity from high catechin concentrations and individual susceptibility through specific UGT polymorphisms. Liver injury typically presents as transaminase elevation 3 to 12 weeks after starting supplementation and resolves on discontinuation. The absolute risk is low (estimated less than 1 per 100,000 user-years) but the consequences can be serious. Sticking to doses below 600 mg/day taken with food essentially eliminates the documented risk. ### Cognitive performance Green tea extract trials with combined L-theanine + caffeine + EGCG show small improvements in attention and working memory, with the bulk of the effect attributable to the L-theanine + caffeine combination rather than EGCG itself. Isolated EGCG cognitive trials are rare and mostly negative. ### Cancer chemoprevention Epidemiology suggests modest associations between high green tea intake and reduced incidence of several cancers (prostate, breast, colorectal). The Polyphenon E pharmaceutical-grade extract trial in prostate cancer (Bettuzzi 2006) reported reduced progression to invasive cancer at 600 mg/day for 12 months, but follow-up trials have been mixed. Treat the cancer evidence as suggestive and population-level rather than as a personal supplementation rationale. ## Dosage and protocols The most-studied dose for metabolic effects is 300 to 600 mg EGCG per day, often as part of a green tea extract standardized to 45 to 90% catechins. Doses above 600 mg/day add side-effect burden without proportionate benefit and approach the EFSA hepatotoxicity threshold. Take with food. The fasted-state hepatotoxicity signal is concentrated in high-dose extracts taken on empty stomach, and food substantially reduces (but does not eliminate) systemic absorption. The trade-off between bioavailability and safety favors fed dosing. No cycling is required for low-dose use. Some users cycle 8 weeks on, 4 weeks off as a precautionary measure for hepatotoxicity, particularly when stacking with other liver-active compounds. Get baseline liver function tests before starting high-dose extracts above 600 mg/day and recheck at 3 months. Decaffeinated green tea extract is a reasonable alternative for caffeine-sensitive users but produces smaller fat-loss effects because the EGCG-caffeine interaction is part of the mechanism. For pure cardiovascular and antioxidant goals, decaffeinated extract or whole green tea consumption (3 to 5 cups daily) is sufficient. ## Side effects and safety GI side effects (nausea, abdominal discomfort, diarrhea) are the most common adverse events at any dose and are dose-dependent. Caffeine-related effects (jitteriness, sleep disturbance, palpitations) appear with caffeinated extracts and are reduced or eliminated with decaffeinated forms. The hepatotoxicity signal is the dominant safety consideration. Onset is typically 4 to 12 weeks after starting high-dose supplementation. Symptoms include fatigue, jaundice, and right-upper-quadrant pain. Liver enzyme elevation is the earliest marker and warrants discontinuation. Recovery on discontinuation is typically complete within 2 to 3 months. Iron absorption is reduced by EGCG through tannin-iron chelation in the gut. Anyone with iron deficiency anemia should avoid EGCG with iron-containing meals or supplements; separating by 2 to 3 hours is sufficient. Drug interactions include modest CYP3A4 modulation (variable direction depending on dose and chronicity), reduced absorption of folate and beta-blockers when taken simultaneously, and additive effects with anticoagulants at high catechin doses. The clinical significance is low at typical supplement doses but warrants attention with narrow-therapeutic-index drugs. Pregnancy use is precautionary. Animal data are mixed, and the EFSA opinion specifically advised against high-dose extracts in pregnancy. Drinking green tea at moderate consumption levels appears safe; supplemental EGCG at high doses is best avoided. ## Stack interactions and timing EGCG combines naturally with caffeine for thermogenic effects and with L-theanine for cognitive layering. The whole-extract approach (50 to 100 mg L-theanine, 80 to 120 mg caffeine, 200 to 400 mg EGCG per dose) is the most-studied stack and a reasonable starting point. Avoid combining EGCG with other potentially hepatotoxic supplements (high-dose niacin, kava, comfrey, ashwagandha at very high doses). The evidence for additive hepatotoxicity is weak but the precaution is worth taking given the EGCG signal. Pair EGCG dosing with breakfast or lunch rather than dinner. Caffeine half-life of 5 hours can disrupt sleep if dosed late, and the bedtime metabolic effects are not different enough to justify late dosing. ## Practical notes Quality varies widely. Look for products that specify EGCG content rather than total catechin content, and ideally show third-party Certificate of Analysis. Pharmaceutical-grade Polyphenon E (used in clinical trials) is the cleanest standard but is rarely available retail. Cost is moderate. A 90-capsule bottle of 500 mg green tea extract at 50% EGCG runs roughly 15 to 25 dollars, making 300 to 500 mg EGCG per day a 15 to 30 cent daily expense. Brewed green tea is cheaper but delivers a fraction of the supplement-extract dose. Storage matters. Catechins oxidize on exposure to air, moisture, and light. Sealed capsules in opaque bottles are stable for 18 to 24 months; bulk powders degrade faster. Freshness affects both potency and the side-effect profile (oxidized extracts produce more GI symptoms). Expect noticeable fat-loss effects (1 to 2 kg over baseline) at 8 to 12 weeks of consistent dosing combined with caloric deficit. Without caloric deficit, the supplement alone produces 0.5 to 1 kg differences from placebo, which is real but small. Cardiovascular marker effects appear at similar timescales.